■证据表明,最容易感染COVID-19的受试者患有合并症或免疫抑制的患者,包括肝移植受者.肝移植功能障碍可能是一种罕见的并发症。一些患者抱怨COVID-19后综合征。这项研究的目的是评估肝移植患者的中期和短期结果。
■在三级转诊中心进行了回顾性病例系列研究。我们在我们中心筛查了845例肝移植(LT)患者。包括2020年3月至2021年4月西班牙疫情期间所有连续的COVID-19LT患者。人口统计,预先存在的合并症,COVID-19感染的临床和放射学数据,在诊断和3个月随访时评估并发症和肝移植功能.
■总的来说,20例LT患者确诊为COVID-19。我们纳入了16例符合纳入标准的患者,分析了8例非住院患者(50%)和8例住院患者(50%)。中位随访时间为5.33个月(IQR3.06~8.26)。一名患者在随访期间死亡。所有患者均出现一定程度的呼吸或功能症状。在3个月的随访中,呼吸困难和疲劳是最常见的症状。尽管有4例患者(25%)部分停用了免疫抑制,但没有报道肝移植功能障碍。1例患者出现心血管并发症。
■我们的结果表明,在COVID-19后3个月,该组患者中存在COVID-19后综合征,伴有轻度残留的身体和心理功能障碍。然而,没有病例的损失或肝功能不全的报道。
OBJECTIVE: The evidence suggests that most vulnerable subjects to COVID-19 infection suffer from patients with comorbidities or immunosuppression, including liver transplant recipients. Liver graft dysfunction may be a rare complication. Some patients complain about the post-COVID-19 syndrome. The aim of this study was to assess medium- and short-term outcomes in liver transplant patients.
METHODS: A retrospective
case series was performed at a tertiary referral center. We screened 845 patients who had liver transplant (LT) in our center. All consecutive LT patients with COVID-19 during the Spanish outbreak from March 2020 to April 2021 were included. Demographics, pre-existing comorbidities, clinical and radiological data of COVID-19 infection, complications, and liver graft function were assessed at diagnosis and 3-month follow-up.
RESULTS: Overall, 20 LT patients were diagnosed with confirmed COVID-19. We included 16 patients that met the inclusion criteria, 8 nonhospitalized (50%) and 8 (50%) hospitalized patients were analyzed. The median follow-up was 5.33 months (IQR 3.06-8.26). One patient died during the follow-up. All patients presented some grade of respiratory or functional symptoms. Dyspnea and fatigue were the most prevalent symptoms during the 3-month follow-up. No liver graft dysfunction were reported despite of partial immunosuppression withdrawal in four patients (25%). One patient had cardiovascular complications.
CONCLUSIONS: Our results suggest the presence of post-COVID-19 syndrome with mild residual physical and psychological dysfunction in this subgroup of patients at 3 months after COVID-19. However, no cases of loss or liver graft dysfunction were reported.